What are the latest funding news in the mental health market? (August 2026)
Download our beautiful pitch about the mental health market
In our mental health market deck, you will find everything you need to understand the market
Mental health companies announced 12 qualifying funding deals worth approximately $259.5 million between March and July 2026.
The latest transactions covered clinical care providers, psychiatric software platforms, AI-supported treatment infrastructure and neuropsychiatric drug developers.
Most of the capital went to companies that were already delivering care or advancing clinical-stage products, rather than businesses developing general wellness tools.
And if you want to better understand this new industry, you can download our pitch covering the mental health market.
Insights
- The 12 mental health funding deals raised approximately $259.5 million, with an average round of $21.6 million but a lower median of $18 million because Gilgamesh Pharmaceuticals raised $60 million.
- Clinical care delivery remained central to mental health investment, with Precise Behavioral, Flourish Health, Handspring Health, InStride Health, Radley Health and Tava Health raising a combined $132.2 million.
- Youth mental health providers attracted $75 million across three rounds, showing sustained investor interest in specialized care for children, adolescents and young adults with complex conditions.
- Five companies with significant AI components raised approximately $105.5 million, although the strongest propositions positioned AI inside supervised clinical workflows rather than as an independent replacement for clinicians.
- Later-stage Series B and Series C rounds accounted for $89 million, suggesting that investors continued to support mental health companies with established payer relationships and measurable commercialization progress.
- Psychiatric drug developers raised $68.8 million across only two deals, demonstrating how biotechnology rounds can materially change market totals even when transaction volumes remain modest.
- Every company in the list was based in or primarily focused on the United States, despite several businesses describing longer-term pharmaceutical or technology opportunities as global.
- Only one company, The Path, operated near the boundary between clinical mental health treatment and consumer wellness, while the other companies had clearer links to licensed care, clinical workflows or regulated treatments.
- No qualifying company disclosed a reliable valuation, which limits comparisons between capital raised, ownership dilution and investors' expectations for future mental health market growth.
As this chart shows, and as featured in our mental health market deck, search interest in men’s mental health has been rising steadily
Summary table of the latest funding deals in the mental health market as of August 2026
We define the mental health market as the set of services and products that diagnose, treat, or clinically manage mental and substance use disorders.
We include licensed providers, facilities, medications, and clinically validated digital tools that are used to assess or treat recognized mental and substance use conditions.
We exclude general wellness, self-help, fitness, and lifestyle products that aim to improve mood or wellbeing but are not used as formal clinical treatment.
You can also read our detailed analysis to understand how funding activity in the mental health market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the mental health market (we update this list every quarter) as well as our ranking of the most funded startups.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Gilgamesh Pharmaceuticals | March 24, 2026 | $60M | Series A | Psychiatric medication & neuropsychiatric biotechnology |
| Blossom Health | March 26, 2026 | $20M | Seed & Series A | Psychiatry care platform & clinical software |
| Jimini Health | March 31, 2026 | $17M | Seed | Clinical mental health AI infrastructure |
| Trayt Health | April 16, 2026 | $7.17M | Private venture | Behavioral health software & care coordination |
| Tava Health | April 21, 2026 | $40M | Series C | Therapy platform & behavioral health infrastructure |
| The Path | May 21, 2026 | $14.3M | Seed | Hybrid AI-supported therapy |
| Psilera | May 28, 2026 | $8.8M | Seed extension | Psychiatric medication development |
| Radley Health | June 2, 2026 | $3M | Seed | Serious mental illness community care |
| InStride Health | June 15, 2026 | $30M | Series C | Specialty youth mental health treatment |
| Handspring Health | July 8, 2026 | $19M | Series B | Virtual youth mental health treatment |
| Flourish Health | July 27, 2026 | $26M | Series A | High-acuity youth mental health care |
| Precise Behavioral | July 29, 2026 | $14.2M | Venture funding | Behavioral health provider & health-system infrastructure |
All the latest funding deals in the mental health market as of August 2026
Precise Behavioral raised $14.2 million in venture funding in July 2026.
When was it?
Precise Behavioral announced the financing on July 29, 2026.
Who are they?
Precise Behavioral provides physician-led psychiatric coverage, clinical staffing and behavioral health technology to hospitals and health systems.
Geographical focus?
Precise Behavioral primarily serves healthcare organizations across the United States.
Why do we include them in the mental health market?
Precise Behavioral belongs in the mental health market because psychiatric treatment and health-system behavioral health infrastructure represent the core of its operations.
What is the company stage?
Precise Behavioral is at the profitable growth stage, with established health-system customers and active virtual and in-person clinical operations.
How much did they raise?
Precise Behavioral raised $14.2 million in this financing round.
What round is it?
Precise Behavioral described the transaction as venture funding and did not announce a conventional Series designation.
Why did they raise?
Precise Behavioral raised the capital to expand health-system partnerships, strengthen its software and AI capabilities and enter additional geographic markets.
Flourish Health raised $26 million in a Series A round in July 2026.
When was it?
Flourish Health announced the Series A financing on July 27, 2026.
Who are they?
Flourish Health sends psychiatrist-led multidisciplinary teams into the homes of young people with serious or complex mental health conditions.
Geographical focus?
Flourish Health currently operates in the United States and is preparing to expand its model nationally.
Why do we include them in the mental health market?
Flourish Health belongs in the mental health market because it provides intensive psychiatric treatment for diagnosed, high-acuity conditions.
What is the company stage?
Flourish Health is at the early growth and product-market-fit stage, with an operating care model and active payer relationships.
How much did they raise?
Flourish Health raised $26 million in the round, bringing reported total funding to approximately $46 million.
What round is it?
Flourish Health raised a Series A round.
Why did they raise?
Flourish Health raised the capital to enter more markets, increase clinical capacity and give health plans an alternative to hospitalization or residential treatment.
This chart, featured in our mental health market deck, compares the main business model options for tele-mental health platforms
Handspring Health raised $19 million in a Series B round in July 2026.
When was it?
Handspring Health announced the financing on July 8, 2026, after an investor published the news one day earlier.
Who are they?
Handspring Health operates a virtual clinic providing evidence-based therapy and behavioral health treatment to young people and their families.
Geographical focus?
Handspring Health serves patients in the United States and is expanding into additional states.
Why do we include them in the mental health market?
Handspring Health belongs in the mental health market because licensed clinical treatment for pediatric and young-adult conditions is its central service.
What is the company stage?
Handspring Health is at the growth stage, with an established clinical workforce, payer relationships and approximately $37 million in cumulative funding.
How much did they raise?
Handspring Health raised $19 million in this round.
What round is it?
Handspring Health raised a Series B round.
Why did they raise?
Handspring Health raised the capital to recruit clinicians, enter more states, expand insurer partnerships and treat patients with more complex needs.
InStride Health raised $30 million in a Series C round in June 2026.
When was it?
InStride Health announced the Series C financing on June 15, 2026.
Who are they?
InStride Health provides insurance-covered specialty treatment for young people with complex anxiety, OCD and related disorders.
Geographical focus?
InStride Health operates in the United States and serves patients approximately seven to 24 years old and their families.
Why do we include them in the mental health market?
InStride Health belongs in the mental health market because it delivers diagnosis-specific psychiatric and psychological treatment.
What is the company stage?
InStride Health is at the growth and scale stage, with established payer adoption, clinical outcomes and rapid reported revenue expansion.
How much did they raise?
InStride Health raised $30 million in this round.
What round is it?
InStride Health raised a Series C round.
Why did they raise?
InStride Health raised the capital to enter new markets, increase specialty capacity and expand relationships with payers and employers.
This chart, featured in our mental health market deck, shows why Talkspace is winning in mental health
Radley Health raised $3 million in a seed round in June 2026.
When was it?
Radley Health announced the close of the seed financing on June 2, 2026.
Who are they?
Radley Health, also known through its RadleyCare brand, provides peer-supported behavioral health care to adults with serious mental illnesses.
Geographical focus?
Radley Health operates in Ohio and is using the financing to launch services in Georgia.
Why do we include them in the mental health market?
Radley Health belongs in the mental health market because its community-based services support adults with diagnosed serious mental illness.
What is the company stage?
Radley Health is at the early commercialization and expansion stage, with an operating model in Ohio and initial multi-state ambitions.
How much did they raise?
Radley Health raised $3 million in the round.
What round is it?
Radley Health raised a seed round.
Why did they raise?
Radley Health raised the capital to recruit peer-support workers, strengthen community partnerships and expand across Ohio and Georgia.
Psilera raised $8.8 million in a seed extension in May 2026.
When was it?
Psilera announced the oversubscribed seed extension on May 28, 2026.
Who are they?
Psilera develops neuroplastogen and psychedelic-derived drug candidates for psychiatric and neurological disorders.
Geographical focus?
Psilera is based in Tampa, Florida, while its pharmaceutical development opportunity is international.
Why do we include them in the mental health market?
Psilera belongs in the mental health market because a substantial part of its pipeline is intended to treat recognized neuropsychiatric conditions.
What is the company stage?
Psilera is at the preclinical biotechnology stage and is preparing its lead compound for an expected first-in-human study.
How much did they raise?
Psilera raised $8.8 million in the seed extension.
What round is it?
Psilera described the transaction as an oversubscribed seed extension.
Why did they raise?
Psilera raised the capital to complete development work and move PSIL-006 toward its first clinical study.
In our mental health market deck, we identify pain points entrepreneurs should prioritize
The Path raised $14.3 million in a seed round in May 2026.
When was it?
The Path announced the seed financing on May 21, 2026.
Who are they?
The Path offers an AI-supported therapy application with structured interactions, crisis protocols and clinical oversight.
Geographical focus?
The Path presents its product as globally accessible, although the company and financing announcement were based in the United States.
Why do we include them in the mental health market?
The Path is included because it positions the product as therapy, uses established therapeutic frameworks and includes crisis and clinical-safety systems.
What is the company stage?
The Path is at the early commercialization stage, with a launched product but limited public evidence of payer adoption or large-scale clinical deployment.
How much did they raise?
The Path raised $14.3 million in the round.
What round is it?
The Path raised a seed round.
Why did they raise?
The Path raised the capital to improve its AI therapy technology, safety infrastructure, personalization and access to professional support.
Tava Health raised $40 million in a Series C round in April 2026.
When was it?
Tava Health announced the Series C financing on April 21, 2026.
Who are they?
Tava Health combines licensed mental health providers, benefits administration, care navigation and clinic operating software.
Geographical focus?
Tava Health focuses on employers, health plans, providers and patients in the United States.
Why do we include them in the mental health market?
Tava Health belongs in the mental health market because its central activity is arranging, delivering and managing formal mental health treatment.
What is the company stage?
Tava Health is at the growth and scale stage and is developing from a provider network into a full-stack behavioral health platform.
How much did they raise?
Tava Health raised $40 million, taking reported total funding to approximately $73 million.
What round is it?
Tava Health raised a Series C round.
Why did they raise?
Tava Health raised the capital to launch new employer benefits, clinic software and care-navigation products while expanding payer and provider adoption.
This market map, featured in our mental health market deck, highlights top companies and startups in the mental health market
Trayt Health raised $7.17 million in a private venture round in April 2026.
When was it?
Public reporting on the Trayt Health financing appeared on April 16, 2026.
Who are they?
Trayt Health provides behavioral health screening, referral coordination, treatment-personalization and clinical outcome tools.
Geographical focus?
Trayt Health is based in California and primarily serves healthcare providers, health plans and state care systems in the United States.
Why do we include them in the mental health market?
Trayt Health belongs in the mental health market because its platform is specifically designed for behavioral health identification, treatment coordination and outcome management.
What is the company stage?
Trayt Health is at the commercial growth stage, with an established product and plans to deploy it across additional states.
How much did they raise?
Trayt Health raised approximately $7.17 million in the financing.
What round is it?
Trayt Health completed a private venture round without announcing a standard Series designation.
Why did they raise?
Trayt Health raised the capital to deploy its integrated behavioral health platform in more states and expand its work with healthcare organizations.
Jimini Health raised $17 million in a seed round in March 2026.
When was it?
Jimini Health announced the seed financing on March 31, 2026.
Who are they?
Jimini Health develops clinician-supervised AI infrastructure that supports behavioral health patients between appointments.
Geographical focus?
Jimini Health primarily focuses on behavioral health organizations in the United States.
Why do we include them in the mental health market?
Jimini Health belongs in the mental health market because its technology operates inside formal, clinician-supervised behavioral health treatment pathways.
What is the company stage?
Jimini Health is at the early commercial and product-market-fit validation stage, with enterprise deployments beginning through large clinical partners.
How much did they raise?
Jimini Health raised $17 million, bringing total reported funding to more than $25 million.
What round is it?
Jimini Health raised a seed round.
Why did they raise?
Jimini Health raised the capital to develop its AI for additional clinical settings and expand deployments with behavioral health systems.
This chart, featured in our mental health market deck, illustrates yearly funding for mental health startups
Blossom Health announced $20 million across seed and Series A funding in March 2026.
When was it?
Blossom Health announced the combined financing on March 26, 2026.
Who are they?
Blossom Health combines psychiatric care with AI software for treatment planning, prescribing, billing and patient communication.
Geographical focus?
Blossom Health is initially focused on psychiatrists and patients in the United States.
Why do we include them in the mental health market?
Blossom Health belongs in the mental health market because its platform is designed around psychiatric diagnosis, medication management and treatment delivery.
What is the company stage?
Blossom Health is at the early commercialization and growth stage after emerging from stealth and beginning to scale nationally.
How much did they raise?
Blossom Health announced $20 million across its seed and Series A financings without separating the amount raised in each round.
What round is it?
Blossom Health announced a combined seed and Series A financing package.
Why did they raise?
Blossom Health raised the capital to recruit psychiatrists, expand nationally and develop its clinical operating system.
Gilgamesh Pharmaceuticals raised $60 million in a Series A round in March 2026.
When was it?
Gilgamesh Pharmaceuticals announced the financing on March 24, 2026.
Who are they?
Gilgamesh Pharmaceuticals develops next-generation medicines for depression and other neuropsychiatric disorders.
Geographical focus?
Gilgamesh Pharmaceuticals is based in the United States and is developing medicines for eventual use in international pharmaceutical markets.
Why do we include them in the mental health market?
Gilgamesh Pharmaceuticals belongs in the mental health market because its clinical and preclinical pipeline is centered on recognized psychiatric disorders.
What is the company stage?
Gilgamesh Pharmaceuticals is at the clinical-stage biotechnology and growth-development stage.
How much did they raise?
Gilgamesh Pharmaceuticals raised $60 million in the financing.
What round is it?
Gilgamesh Pharmaceuticals raised an oversubscribed Series A round.
Why did they raise?
Gilgamesh Pharmaceuticals raised the capital to advance several neuropsychiatric drug candidates through clinical development and expand its discovery programs.
Related blog posts
- How strong is fundraising in the mental health market right now?
- The full range of business models in the mental health market
- How big is the mental health market really?
- The evolution of funding activity in the mental health market
- The main fundraising trends in the mental health market
- An overview of all funding deals in the mental health market
- The startups that have raised the most funding in the mental health market
- The most highly valued startups in the mental health market
